see comments on motley fool article, page-2

The emphasis on beta amyloid clearance is based on previous drug strategies which are all focused on bombarding beta amyloid and plaque formation with unfortunate negative side effects.

MPACs and prana's strategy are focused on early intervention that maintains metal homeostasis within the brain, maintaining cognitive function and therefore theoretically avoids plaque production as well.

The phase iia trial of pbt2 was exciting as they saw minimal side effects between the three treatment arms (placebo, 100 and 250mg). We also saw some early 12 week signs of improvement in executive functioning for two of the cognitive tests, which was surprising to say the least, however more research was necessary. Hence the scientific process and hence the phase iib trial.

So in summary, prana is a very different MOA to other drug failures mentioned in the motley fool analysis and other commentaries, particularly in regards to metal homeostasis.

I sense the recent drop is due to some profit taking, but also some commentary that links pbt2 MOA to other pharmacological interventions that have previously been trialled by other companies and failed.

PBT2 is differentiated clearly from these other failures in their mode of action. We don't have a definitive answer as to whether PBT2 is the answer, but phase iia was encouraging.....

and....

end of march is only 6 weeks away....

everyone needs to do their own research....

but I am very keen to see what stone they have uncovered with the upcoming trial results. I don't have any reliable indication in front of me that says that pbt2 is not the answer and I await with a sly grin to see if pbt2 is the answer.

Good luck to all and invest only that which you may be prepared to lose.